GeminIQ Website Logo

Viewing LBRX free

Subscribe for full history, 90+ metrics, screener, watchlist...

LB PHARMACEUTICALS INC

LBRX

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Assets
Cash And Cash Equivalents At Carrying Value
283321250270
Assets Current
Assets Current
355389308316
Marketable Securities Current
45454545
Prepaid Expense And Other Assets Current
2823132
Operating Lease Right Of Use Asset
3222
Property Plant And Equipment Net
2222
Restricted Cash Noncurrent
1111
Assets
362393313321
Liabilities And Stockhold…
Accounts Payable Current
3723
Liabilities Current
Accrued Liabilities Current
19353
Liabilities Current
241177
Operating Lease Liability Current
1111
Derivative Liabilities Noncurrent
1111
Operating Lease Liability Noncurrent
4333
Liabilities
29151211
Statement Of Stockholders…
Temporary Equity
Common Stock Value
0000
Additional Paid In Capital Common Stock
532527431428
Retained Earnings Accumulated Deficit
-200-149-130-118
Accumulated Other Comprehensive Income Loss Net Of…
000-0
Stockholders Equity
332379301310
Liabilities And Stockholders Equity
362393313321
Common Stock Par Or Stated Value Per Share
0000
Common Stock Shares Authorized
500500500500
Common Stock Shares Issued
29292525
Preferred Stock Par Or Stated Value Per Share
-000
Shares Outstanding
29292525
Preferred Stock Shares Authorized
-101010

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-8.35%7.39%31.38%---------
2025------14.70%38.81%54.16%24.42%20.91%15.86%

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
15.08
35.68
41.44
47.60
Quick Ratio
13.91
33.53
39.67
47.31
Working Capital
331.74M
378.17M
300.99M
309.75M
Leverage & Debt
Debt to Equity
0.09
0.04
0.04
0.03
Debt Ratio
0.08
0.04
0.04
0.03
Efficiency & Turnover
Asset Turnover TTM
0.00
-
-
-
Per Share Metrics
Diluted EPS TTM
-3.18
-
-
-
Free Cash Flow Per Share TTM
-2.43
-
-
-
Dividend Per Share TTM
0.00
-
-
-
Valuation Metrics
P/E TTM
-10.20
-
-
-
P/B TTM
2.94
1.84
0.59
0.30
Market Cap
978.12M
696.44M
179.08M
91.69M
Enterprise Value
695.01M
375.76M
-71.09M
-178.05M
Calculated Values
Free Cash Flow TTM
-73.25M
-
-
-
Net Debt
-283.11M
-320.68M
-250.17M
-269.74M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2025-09-12Purchase
Owner: Pontifax, Management 4 G.…
Title: -
Shares: 1,000,000
Price/Share: $15.00
Value: $15,000,000.00
Shares Owned: 1,411,681
Relationship: TenPercentOwner
Ownership: Indirect
2025-09-12Purchase
Owner: Deep, Track Capital, Lp, …
Title: -
Shares: 2,000,000
Price/Share: $15.00
Value: $30,000,000.00
Shares Owned: 2,686,138
Relationship: TenPercentOwner
Ownership: Direct
2025-09-12Purchase
Owner: Nussbaum, Ran
Title: -
Shares: 1,000,000
Price/Share: $15.00
Value: $15,000,000.00
Shares Owned: 1,411,681
Relationship: Director
Ownership: Indirect
2025-09-12Purchase
Owner: Vida, Ventures Gp Iii, L.…
Title: -
Shares: 333,333
Price/Share: $15.00
Value: $4,999,995.00
Shares Owned: 880,214
Relationship: TenPercentOwner
Ownership: Indirect

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
94.79%
Inst. Shares: 26,769,129
Shares Outstanding: 28,241,701
2025-12-31
-
Inst. Shares: 24,771,472
Shares Outstanding: 8,045,145
2025-09-30
-
Inst. Shares: 19,604,737
Shares Outstanding: 5,806,862

LB PHARMACEUTICALS INC (LBRX) — SEC Financial Statements & Analysis

LB PHARMACEUTICALS INC (LBRX) is a pharmaceutical preparations company, incorporated in DE. LB PHARMACEUTICALS INC trades on Nasdaq as: LBRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), LB PHARMACEUTICALS INC reported a Debt-to-Equity ratio of 0.09x, a Price-to-Book (P/B) ratio of 2.94x (TTM), at a market cap of $978.12M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
0.09x
P/B TTM
2.94x
Market Cap
$978.12M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is LB PHARMACEUTICALS INC in?

LB PHARMACEUTICALS INC (LBRX) operates in the Pharmaceutical Preparations industry.

What is LBRX's market cap?

LB PHARMACEUTICALS INC (LBRX) has a market capitalization of $978.12M as of 2026-06-30.

What exchange does LBRX trade on?

LB PHARMACEUTICALS INC (LBRX) trades on the Nasdaq.

Where is LB PHARMACEUTICALS INC incorporated?

LB PHARMACEUTICALS INC is incorporated in DE.

Wall Street's data.
Main Street's price.